Skip to main content

Analysts Offer Insights on Healthcare Companies: Ufp Technologies (UFPT) and MiMedx Group (MDXG)

Tipranks - Fri Feb 27, 8:20AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ufp Technologies (UFPTResearch Report) and MiMedx Group (MDXGResearch Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Ufp Technologies (UFPT)

In a report released today, Max Michaelis from Lake Street reiterated a Buy rating on Ufp Technologies, with a price target of $289.00. The company’s shares closed last Wednesday at $240.16.

According to TipRanks.com, Michaelis is a 5-star analyst with an average return of 67.8% and a 57.8% success rate. Michaelis covers the Technology sector, focusing on stocks such as Benchmark Electronics, Aehr Test Systems, and Quantum Computing. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ufp Technologies with a $289.00 average price target.

See today’s best-performing stocks on TipRanks >>

MiMedx Group (MDXG)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on MiMedx Group, with a price target of $10.00. The company’s shares closed last Wednesday at $5.28.

According to TipRanks.com, Takkinen is a 1-star analyst with an average return of -0.7% and a 39.3% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Adagio Medical Holdings, and TriSalus Life Sciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $9.60 average price target, representing a 79.1% upside. In a report issued on February 23, Citizens JMP also initiated coverage with a Buy rating on the stock with a $10.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.